Literature DB >> 19347827

Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.

Catherine Uzan1, Fabrice Andre, Veronique Scott, Isabelle Laurent, Elie Azria, Voichita Suciu, Corinne Balleyguier, Ludovic Lacroix, Suzette Delaloge, Philippe Vielh.   

Abstract

BACKGROUND: With the widespread development of genomic analysis, an accurate and quick method for obtaining high-quality nucleic acids is needed. The objective of the current study was to evaluate the quality and potential use of material obtained from fine-needle aspiration cytology (FNAC).
METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions. The authors evaluated the amount of messenger RNA (mRNA) obtained, its quality through the RNA Integrity (RIN) score, and the factors that influenced both. For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen.
RESULTS: The amount of mRNA obtained was >1 microg in 89.5% of 124 samples (43 benign lesions and 81 adenocarcinomas). Overall, 59.3% of samples yielded >1 microg RNA with a RIN score >6. The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion. The median ESR1 expression level, which was expressed as the polymerase chain reaction cycle threshold (CT) level minus the average 18S value (dct), was 17.7 dct in patients with estrogen receptor-negative tumors and 11.1 dct in patients with estrogen receptor-positive tumors. The median HER-2 expression level was 15.1 dct in patients with HER-2-negative tumors and 10.7 dct in patients with HER-2-positive tumors. mRNA expression was concordant with the IHC/FISH evaluation in 90.3% of patients for estrogen receptor status and in 98.5% of patients for HER-2 status.
CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347827     DOI: 10.1002/cncy.20008

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer.

Authors:  Laura Annaratone; Caterina Marchiò; Tommaso Renzulli; Isabella Castellano; Daniela Cantarella; Claudio Isella; Luigia Macrì; Giovanna Mariscotti; Davide Balmativola; Elisabetta Cantanna; Cristina Deambrogio; Francesca Pietribiasi; Riccardo Arisio; Fernando Schmitt; Enzo Medico; Anna Sapino
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

2.  Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.

Authors:  Claudia Rodriguez; Voichita Suciu; Audrey Poterie; Ludovic Lacroix; Isabelle Miran; Amélie Boichard; Suzette Delaloge; Jacqueline Deneuve; Sandy Azoulay; Marie-Christine Mathieu; Alexander Valent; Stefan Michiels; Monica Arnedos; Philippe Vielh
Journal:  Mol Oncol       Date:  2016-08-05       Impact factor: 6.603

Review 3.  Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology.

Authors:  Céline Bourgier; Mahmut Ozsahin; David Azria
Journal:  Radiat Oncol       Date:  2010-01-14       Impact factor: 3.481

4.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

5.  Fine-needle aspiration cytology can play a role in neoadjuvant chemotherapy in operable breast cancer.

Authors:  Christian Garbar; Hervé Curé
Journal:  ISRN Oncol       Date:  2013-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.